Your browser is no longer supported. Please, upgrade your browser.
Settings
FRLN [NASD]
Freeline Therapeutics Holdings plc
Index- P/E- EPS (ttm)- Insider Own8.23% Shs Outstand35.85M Perf Week-4.03%
Market Cap170.64M Forward P/E- EPS next Y-3.77 Insider Trans0.00% Shs Float12.37M Perf Month-41.60%
Income- PEG- EPS next Q-0.97 Inst Own33.84% Short Float0.28% Perf Quarter-56.73%
Sales- P/S- EPS this Y39.10% Inst Trans- Short Ratio0.20 Perf Half Y-73.54%
Book/sh- P/B- EPS next Y2.80% ROA- Target Price- Perf Year-
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range4.26 - 21.69 Perf YTD-73.93%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-78.05% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low11.74% ATR0.97
Employees236 Current Ratio- Sales Q/Q- Oper. Margin- RSI (14)25.47 Volatility12.21% 17.40%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.82 Prev Close4.75
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume172.16K Price4.76
Recom1.80 SMA20-29.41% SMA50-42.27% SMA200-64.72% Volume141,744 Change0.21%
May-19-21Initiated H.C. Wainwright Buy $30
May-06-21Initiated Guggenheim Buy $17
Mar-23-21Initiated Mizuho Buy $27
Mar-02-21Initiated Stifel Buy $21
Jun-30-21 04:01PM  
Jun-22-21 10:34PM  
Jun-16-21 07:00AM  
May-26-21 11:06AM  
May-17-21 04:02PM  
May-12-21 07:00AM  
May-11-21 07:00AM  
Apr-27-21 04:31PM  
Apr-21-21 04:01PM  
Mar-31-21 04:02PM  
Mar-30-21 04:01PM  
Mar-11-21 07:00AM  
Mar-02-21 07:00AM  
Feb-18-21 03:11AM  
Feb-16-21 07:00AM  
Feb-09-21 07:30AM  
Feb-08-21 04:01PM  
12:47PM  
07:00AM  
Jan-26-21 07:00AM  
Jan-04-21 07:00AM  
Dec-14-20 07:00AM  
Dec-11-20 12:01AM  
Nov-19-20 07:00AM  
Nov-13-20 06:37AM  
Nov-02-20 07:00AM  
Oct-30-20 07:00AM  
Oct-29-20 04:15PM  
Sep-29-20 07:00AM  
Sep-28-20 07:00AM  
Sep-25-20 07:00AM  
Sep-23-20 07:00AM  
Sep-14-20 12:02PM  
Sep-10-20 07:00AM  
Aug-07-20 02:49AM  
Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases. Its advanced product candidate is FLT180a, a gene therapy product candidate that is in Phase 1/2 dose-finding clinical trials in adult males for the treatment of hemophilia B. The company's products also include FLT190, which is in dose-escalating Phase 1/2 clinical trials for the treatment of Fabry disease; FLT201, a liver-directed gene therapy product candidate to treat type 1 Gaucher disease; and FLT210, a liver-directed gene therapy product candidate for the treatment of hemophilia A. In addition, it has research programs in various indications for systemic gene therapy. The company was founded in 2015 and is headquartered in Stevenage, the United Kingdom.